Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent

The Journal of Clinical Endocrinology and Metabolism
M T CollinsS J Marx

Abstract

Parathyroid carcinoma is one cause of primary hyperparathyroidism, a condition in which there is hypercalcemia and dysregulated hypersecretion of PTH. In normal, and in some neoplastic parathyroid cells, PTH secretion is mediated by the cell surface calcium-sensing receptor. We describe the first therapeutic use of a novel molecule, a calcimimetic, that has agonist action at the calcium-sensing receptor. A 78-yr-old man with parathyroid carcinoma was admitted with hypercalcemia, markedly elevated PTH, and a change in mental status. He was treated for 17 days with conventional therapy, which included saline hydration, furosemide, pamidronate, and calcitonin. This was ineffective, and on hospital day 18, calcimimetic at a dose of 50 mg, orally, every 6 h was added. On hospital day 25, the dose was increased to 100 mg, orally, every 6 h, and on hospital day 30, saline and furosemide were discontinued. He was discharged on hospital day 40. With several dose adjustments, he has been treated with monotherapy calcimimetic for over 600 days and has not required any other interventions for his parathyroid carcinoma. Mean daily precalcimimetic treatment values of serum ionized calcium and PTH were 1.83 mmol/L and 872 pg/mL, respectively....Continue Reading

Citations

Nov 20, 2009·American Journal of Physiology. Renal Physiology·Daniela Riccardi, Edward M Brown
Feb 9, 1999·Lancet·A R Bradwell, T C Harvey
Sep 8, 2006·Journal of Endocrinological Investigation·P ValdivielsoJ J Sánchez-Carrillo
Mar 1, 2006·World Journal of Surgical Oncology·Corrie L MessererSam M Wiseman
Apr 8, 2009·World Journal of Surgery·Takahiro OkamotoToshihiko Tsukada
Aug 29, 2003·Current Treatment Options in Oncology·Tobias Carling, Robert Udelsman
Jun 12, 2002·Current Treatment Options in Oncology·E Kebebew
Jun 4, 2005·Langenbeck's Archives of Surgery·Maurizio IacoboneGennaro Favia
Jul 29, 2003·Expert Opinion on Investigational Drugs·Nora FranceschiniAbhijit Kshirsagar
Mar 12, 2004·Expert Opinion on Investigational Drugs·Alberto Falchetti
Sep 21, 2013·Drug Discovery Today. Technologies·E F Nemeth
May 2, 2002·Kidney International. Supplement·João M FrazãoJack W Coburn
Jan 14, 2000·Kidney International. Supplement·J W CoburnJ M Frazaõ
Jan 14, 2000·Kidney International. Supplement·E RitzJ Bommer
May 20, 2003·Kidney International. Supplement·Pablo Ureña, João M Frazão
Dec 21, 2010·Seminars in Oncology·John M SharrettsWilliam F Simonds
Jul 25, 2009·Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición·Manuel Muñoz Torres, Antonia García Martín
Mar 4, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Walter H Hörl
Aug 3, 2006·Surgical Oncology Clinics of North America·Brian Lang, Chung-Yau Lo
Jul 11, 2006·Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation·Pablo Ureña Torres
Dec 28, 2005·Surgical Neurology·Seiichi Yoshida
Jun 12, 2002·Endocrinology and Metabolism Clinics of North America·Leonard J Deftos
Mar 11, 2015·Seminars in Dialysis·Mariano RodríguezJohn Cunningham
Oct 14, 2004·The Annals of Pharmacotherapy·Melanie S JoyNora Franceschini
Apr 27, 2001·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·O M Hauache
Aug 6, 2000·British Journal of Anaesthesia·R Mihai, J R Farndon
Feb 26, 2004·Cancer·Gary L ClaymanRena Vassilopoulou-Sellin
Nov 12, 2017·British Journal of Pharmacology·Fadil M HannanRajesh V Thakker
Aug 3, 2004·Head & Neck·Naifa L BusaidyRena Vassilopoulou-Sellin
Jan 24, 2007·Nature Clinical Practice. Endocrinology & Metabolism·Edward M Brown
Feb 19, 2005·Journal of Surgical Oncology·Elizabeth A Mittendorf, Christopher R McHenry
Nov 27, 2007·European Journal of Clinical Investigation·R P WüthrichJ P Bilezikian
Nov 29, 2007·Current Opinion in Oncology·Steven E RodgersCarmen C Solórzano
Aug 26, 2006·Nature Clinical Practice. Nephrology·Irina ShahapuniAlbert Fournier
Oct 21, 2005·The British Journal of Surgery·N RawatJ N Baxter
Mar 4, 2005·Treatments in Endocrinology·Manuel Muñoz-TorresMezquita Pedro Raya
Aug 2, 2007·The Journal of Clinical Endocrinology and Metabolism·S J SilverbergJ P Bilezikian
Nov 2, 2013·The Journal of Clinical Endocrinology and Metabolism·Priyathama VellankiMalek El Muayed
Jan 6, 2005·Endocrine Reviews·Stephen J Marx, William F Simonds
Feb 6, 2009·The Journal of Clinical Endocrinology and Metabolism·Aliya KhanDolores Shoback
Apr 29, 1998·The Journal of Clinical Endocrinology and Metabolism·S M Ott

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.